TERAPIYa EREKTIL'NOY DISFUNKTsII POSLE RADIKAL'NOY PROSTATEKTOMII


Cite item

Full Text

Abstract

References

  1. Пушкарь Д. Ю., Раснер П. И. Диагностика и лечение локализованного рака предстательной железы. М.: МЕДпресс-информ; 2008.
  2. Moreland R. B. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int. J. Impot. Res. 1998; 10: 113-120.
  3. McCullough A. Penile change following radical prostatectomy: size, smooth muscle atrophy, and curve. Curr. Urol. Rep. 2008; 9 (6): 492-499.
  4. Klein L. T., Miller M. I., Buttyan R. et al. Apoptosis in the rat penis after penile denervation. J. Urol. (Baltimore) 1997; 158: 626-630.
  5. De Luca V., Pescatori E. S., Taher B. et al. Damage to the erectile function following radical pelvic surgery: prevalence of veno-occlusive dysfunction. Eur. Urol. 1996; 29: 36-40.
  6. Albersen M., Joniau S., Claes H., Van Poppel H. Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy. Adv. Urol. 2008; Article ID 594868. Published online 2008 June 25. doi: 10.1155/2008/ 594868. PMCID: PMC2441891.
  7. Al Shaiji T., Domes T., Brock G. Penile rehabilitation following treatment for prostate cancer: an analysis of the current state of the art. Can. Urol. Assoc. J. 2009; 3 (1): 37-48.
  8. Gontero P., Galzerano M., Bartoletti R. et al. New insights into the pathogenesis of penile shorttening after radical prostatectomy and the role of postoperative sexual function. J. Urol. (Baltimore) 2007; 178 (2): 602-607.
  9. Savoie M., Kim S. S., Soloway M. S. A prospective study measuring penile lenght in men treated with radical prostatectomy for prostate cancer. J. Urol. (Baltimore) 2003; 169 (4): 1462-1464.
  10. Hinh P., Run Wang. Overview of contemporary penile rehabilitation therapies. Adv. Urol. 2008; Article 481218. Published online 2008 September 4. doi: 10.1155/2008/481218. PMCID: PMC2531200.
  11. Hatzimouratidis K., Burnett A. L., Hatzichristou D. et al. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur. Urol. 2009; 55 (2): 334-347.
  12. Montorsi F., Padma-Nathan H., McCullough A. et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J. Urol. (Baltimore) 2004; 172 (3): 1036-1041.
  13. Bannowsky A., Schulze H., van der Horst C. et al. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. Br. J. Urol. Int. 2008; 101: 1279-1283.
  14. McCullough A. R., Levine L. A., Padma-Nathan H. Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil ditrate: subanalysis of a longitudinal randomized double-blind placebo-controlled Trial. J. Sex. Med. 2008; 5 (2): 475- 484.
  15. McCullough A. R. Rehabilitation of erectile function following radical prostatectomy. Asian J. Androl. 2008; 10 (1): 61-74.
  16. Raina R., Lakin M. M., Agarwal A. et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004; 63 (5): 960-966.
  17. Feng M. I., Huang S., Kaptein J. et al. Effect of sildenafil citrate on post-radical prostatectomy erectile dysfunction. J. Urol. (Baltimore) 2000; 164: 1935-1938.
  18. Hong E. K., Lepor H., McCullough A. R. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int. J. Impot. Res. 1999; 11 (suppl. 1): S15-S22.
  19. Nehra A., Grantmyre J., Nadel A. et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J. Urol. (Baltimore) 2005; 173: 2067-2071.
  20. Brock G., Nehra A., Lipshultz L. I. et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J. Urol. (Baltimore) 2003; 170: 1278-1283.
  21. Padma-Nathan H., McCullough A. R., Levine L. A. et al. Randomized, double-blind, placebo-controlled stydy of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int. J. Impot. Res. 2008; 20: 479-486.
  22. Kovanecz I., Rambhatla A., Ferrini M. et al. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int. J. Impot. Res. 2008; 20: 202-212.
  23. Ferrini M. G., Davila H. H., Kovanecz I. et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006; 68: 429-435.
  24. Kovanecz I., Rambhatla A., Ferrini M. G. et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. Br. J. Urol. Int. 2008; 101: 203-210.
  25. Schwartz E. J., Wong P., Graydon R. J. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J. Urol. (Baltimore) 2004; 171: 771-774.
  26. Mulhall J., Land S., Parker M. et al. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J. Sex. Med. 2005; 2 (4): 532-540; discus.: 540-542.
  27. Zumble J., Porst H., Sommer F. et al. Comparable efficacy of once-daily versus on-demand vardenafil in men mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur. Urol. 2008; 54: 204-210.
  28. Montorsi F., Brock G., Lee J. et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur. Urol. 2008; 54: 924-931.
  29. Ruiz Rubio J. L., Hernandez M., Rivera de los Arcos L. et al. Mechanisms of prostaglandin E1-induced relaxation in penile resistance arteries. J. Urol. (Baltimore) 2004; 171: 968-973.
  30. McCullough A. R., Alukal J., Bytyc A., Goodwin B. The longitudinal effects on penile oxygen saturation from a prospective randomized stydy of the nihtly use of intraurethral alprostadil vs sildenafil follows nerve sparing radical prostatectomy (NSRP). J. Urol. (Baltimore); 2009; 181 (4, suppl.): 525.
  31. Bechara A., Casabй A., Cheliz G. et al. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J. Urol. (Baltimore); 1997; 157 (6): 2132-2134.
  32. Bechara A., Casabe A., Cheliz G. et al. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in non-responders to hgh papaverine ;lus phentolamine doses. J. Urol. (Baltimore); 1996; 155: 913-914.
  33. Raina R., Lakin M. M., Thukral M. et al. Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int. J. Impot. Res. 2003; 15: 318-322.
  34. Kava B. R. Advances in the management of post-radical prostatectomy erectile dysfunction: treatment strategies when PDE-5 inhibitors don't work. Rev. Urol. 2005; 7 (suppl. 2): S39-S50.
  35. Lakin M. M., Montague D. K., VanderBrug Medendorp S. et al. Intracavernous injection therapy: analysis of results and complications. J. Urol. (Baltimore); 1990; 143: 1138-1141.
  36. Brock G., Tu L. M., Linet O. I. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Urology 2001; 57: 536-541.
  37. Montorsi F., Guazzoni G., Strambi L. F. et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J. Urol. (Baltimore) 1997; 158 (4): 1408-1410.
  38. Gontero P., Fontana F., Bagnasacco A. et al. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J. Urol. (Baltimore); 2003; 196 (6): 2166-2169.
  39. Mombet A., Cathala N., Cathelineau X. et al. Penile rehabilitation after laparoscopic radical prostatectomy leads to improved erectile function. J. Urol. (Baltimore) 2009; 181 (4, suppl.): 524.
  40. Montorsi F., Briganti A. et al. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur. Urol. 2004; 45: 123-133.
  41. Lepor H., McCullough A. Penile rehabilitation post-prostatectomy: Is there a role for MUSE? Rev. Urol. 2008; 10: 1-5.
  42. Raina R., PahlajaniG., Agarwal A. et al. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier of erectile function and successful sexual activity. Br. J. Urol. Int. 2007; 100: 1317-1321.
  43. Bratton R. L., Cassidy H. D. Vacuum erection device use in elderly men: a possible severe complication. J. Am. Board Fam. Pract. 2002; 15 (6): 501-502.
  44. Dalkin B. L., Christopher B. A. Preservation of penile length after radical prostatectomy: early intervention with a vacuum erection device. Int. J. Impot. Res. 2007; 19 (5): 501-504.
  45. Raina R., Agarwal A., Ausmundson S. et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int. J. Impot. Res. 2006; 18 (1): 77-81.
  46. Kцhler T. S., Pedro R., Hendlin K. et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. Br. J. Urol. Int. 2007; 100 (4): 858-862.
  47. Bosshardt R. J., Farwerk R., Sikora R. et al. Objective measurement of the effectiveness, therapeutic success and dynamic mechanisms of the vacuum device. Br. J. Urol. 1995; 75 (6): 786-791.
  48. Dorey G., Speakman M. J., Feneley R. C. et al. Pelvic floor exercises for erectile dysfunction. Br. J. Urol. Int. 2005; 96 (4): 595-797.
  49. Van Kampen M., De Weerdt W., Claes H. et al. Treatment of erectile dysfunction by perineal exercise, electromyographic biofeedback, and electrical stimulation. Phys. Ther. 2003; 83 (6): 536-543.
  50. Prota C., Ribeiro L., Gomes C. et al. Early pelvic-floor biofeedback training promotes improvement of erectile function after radical prostatectomy. J. Urol. (Baltimore) 2009; 181 (4, suppl.): 524-525.
  51. Mьller A., Tal R., Donohue J. F. The effect of hyperbaric oxygen therapy on erectile function recovery in a rat cavernous nerve injury model. J. Sex. Med. 2008; 5 (3): 562-570.
  52. Мужское здоровье и дисфункция репродуктивной системы / Под ред. Э. Нишлага, Г. М. Бере; пер .с англ. под ред. И. И. Дедова. М.: Мед. информ. агентство; 2005.
  53. Rhoden E. L., Averbeck M. A., Teloken P. E. Androgen replacement in men undergoing treatment for prostate cancer. J. Sex. Med. 2008; 5 (9): 2202-2208.
  54. Isbarn H., Pinthus J. H., Marks L. S. et al. Testosterone and prostate cancer: Revisiting old paradigms. Eur. Urol. 2009; 56 (1): 48-56.
  55. Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J. Urol. (Baltimore) 2009; 181 (3): 972-979.
  56. Khera M., Grober E. D., Najari B. et al. Testosterone replacement therapy following radical prostatectomy. J. Sex. Med. 2009; 6 (4): 1165-1170.
  57. Agarwal P. K., Oefelein M. G. Testosterone replacement therapy after primary treatment for prostate cancer. J. Urol. (Baltimore) 2005; 173 (2): 533-536.
  58. Pushkar D. Y., Govorov A. V., Segal A. S. Androgen replacement therapy in patients with agerelated hypogonadism after radical retropubic prostatectomy for localized prostate cancer. J. Men's Hlth 2008; 5 (3): 234-238.
  59. Dadkhah F., Safarinejad M. R., Asgari M. A. et al. Atorvastatin improves the response to silenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int. J. Impot. Res. 2010; 22 (1): 51-60.
  60. Hong S. K., Han B. K., Jeong S. J. et al. Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy. J. Urol. (Baltimore) 2007; 178 (2): 613-616.
  61. Ситников Н. В. Профилактика осложнений и ранняя реабилитация больных после радикальной простатэктомии: Дис. ... д-ра мед. наук. - М., 2008.
  62. Cavallini G., Modenini F., Vitali G., Koverech A. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology 2005; 66 (5): 1080- 1085.
  63. Parsons J. K., Marschke P., Maples P., Walsh P. C. Effect of methylprednisolone on return of sexual function after nerve-sparing radical retropubic prostatectomy. Urology 2004; 64 (5): 987-990.
  64. Kaminska B., Gaweda-Walerych K., Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants - facts and hypotheses. J. Cell. Mol. Med. 2004; 8 (1): 45-58.
  65. Gold B. G., Katoh K., Storm-Dickerson T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J. Neurosci. 1995; 15 (11): 7509-1675.
  66. Lee M., Doolabh V. B., Mackinnon S. E., Jost S. FK506 promotes functional recovery in crushed rat sciatic nerve. Muscle and Nerve 2000; 23 (4): 633-640.
  67. Burnett A. L., Becker R. E. Immunophilin liands promote penile neurogenesis and erection recovery after cavernous nerve injury. J. Urol. (Baltimore) 2004; 171 (1): 495-500.
  68. Lagoda G., Jin L., Lehrfeld T. J. et al. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J. Sex. Med. 2007; 4 (4, Pt 1): 908-916.
  69. Fleischmann R., Iqbal I., Stern R. L. Tacrolimus in rheumatoid arthritis. Expert. Opin. Pharmacother. 2006; 7 (1): 91-98.
  70. Valentine H., Chen Y., Guo H. et al. Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: new experimental paradigms. Eur. Urol. 2007; 51 (6): 1724-1731.
  71. Bella A. J., Hayashi N., Carrion R. E. et al. FK1706 enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat. J. Sex. Med. 2007; 4 (2): 341- 346; discus.: 346-347.
  72. Hayashi N., Minor T. X., Carrion R. et al. The effect of FK1076 on erectile function following bilateral cavernous nerve crush injury in a rat model. J. Urol. (Baltimore) 2006; 176 (2): 824-829.
  73. Bella A. J., Lin G., Catgiannos I., Lue T. F. Emerging neuromodulatory molecules for the treatment of neurogenic erectile dysfunction caused by cavernous nerve injury. Asian. J. Androl. 2008; 10 (1): 54-59.
  74. Chen K. C., Minor T. X., Rahman N. U. et al. The additive erectile recovery effect of brain-derived neurotrophic factor combined with vascular endothelial growth factor in a rat model of neurogenic impotence. Br. J. Urol. Int. 2005; 95 (7): 1077- 1080.
  75. Laurikainen A., Hiltunen J. O., Thomas-Crusells J. et al. Neurturin is a neurotrophic factor for penile parasympathetic neurons in adult rat. J. Neurobiol. 2000; 43 (2): 198-205.
  76. Leitner M. L., Molliver D. C., Osborne P. A. et al. Analisis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRalpha coreceptor-specific. J. Neurosci. 1999; 19 (21): 9322-9331.
  77. Bella A. J., Fandel T. M., Tantiwongse K. e al. Neurturin enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat. J. Brachial Plex. Peripher. Nerve Inj. 2007; 2: 5.
  78. Fandel T. M., Bella A. J., Tantiwongse K. et al. The effect of intracavernosal growth differentiation factor-5 therapy in a rat model of cavernosal nerve injury. Br. J. Urol. Int. 2006; 98 (3): 632-636.
  79. Liu T., Allaf M. E., Lagoda G., Burnett A. L. Erythropoietin receptor expression in the human urogenital tract: immunolocalization in the prostate, neurovascular bundle and penis. Br. J. Urol. 2007; 100 (5): 1103-1106.
  80. Li X., Gonias S. L., Campana W. M. Schwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injury. Glia 2005; 51 (4): 254-265.
  81. Allaf M. E., Hoke A., Burnett A. L. Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J. Urol. (Baltimore) 2005; 174 (5): 2060-2064.
  82. Song Y. S., Lee H. J., Park I. H. et al. Potential differentiation of human mesenchymal stem cell transplanted in rat corpus cavernosum toward endothelial or smooth muscle cells. Int. J. Impot. Res. 2007; 19 (4): 378-385.
  83. Song Y. S., Lee H. J., Park I. H. et al. Human neural crest stem cells transplanted in rat penile corpus cavernosum to repair erectile dysfunction. Br. J. Urol. Int. 2008; 102 (2): 220-224; discus.: 224.
  84. Bochinski D., Lin G. T., Nunes L. et al. The effect of neural embryonic stem cell trerapy in a rat model of cavernosal nerve injury. Br. J. Urol. Int. 2004; 94 (6): 904-909.
  85. Велиев Е. И., Ванин А. Ф., Котов С. В., Шишло В. К. Современные аспекты патофизиологии и профилактики эректильной дисфункции и кавернозного фиброза после радикальной простатэктомии. Урология 2009, N2: 46.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies